Enterprise Therapeutics, a drug discovery company developing novel therapies for the treatment of respiratory diseases, announced its TMEM16A potentiator portfolio has been fully acquired by Roche and will be developed by Genentech, a member of the Roche Group. The portfolio includes ETD002, a first-in-class inhaled cystic fibrosis (CF) therapy, which is currently in Phase 1.
TMEM16A (ANO1, anoctamin-1) is a calcium-activated chloride channel expressed in airway secretory epithelia. TMEM16A potentiation is regarded as a promising novel approach for the treatment of patients with CF and also non-CF lung diseases.
In preclinical models, ETD002 enhanced the activity of TMEM16A, increased epithelial fluid secretion and enhanced mucus clearance.
Photo by CDC on Unsplash